2026-04-29T02:37:58Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/115002025-06-24T11:31:44Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19608

00925njm 22002777a 4500 dc Rondy, M author Wiessing, L author Hutchinson, S J author Matheï, C author Mathis, F author Mravcik, V author Norden, L author Rosińska, M author Scutelniciuc, O author Suligoi, B author Vallejo-Ruiz de Leon, Fernando author Van Veen, M author Kretzschmar, M author 2013-03 Monitoring injecting drug users' (IDUs) health is challenging because IDUs form a difficult to reach population. We examined the impact of recruitment setting on hepatitis C prevalence. Individual datasets from 12 studies were merged. Predictors of HCV positivity were sought through a multilevel analysis using a mixed-effects logistic model, with study identifier as random intercept. HCV prevalence ranged from 21% to 86% across the studies. Overall, HCV prevalence was higher in IDUs recruited in drug treatment centres compared to those recruited in low-threshold settings (74% and 42%, respectively, P < 0·001). Recruitment setting remained significantly associated with HCV prevalence after adjustment for duration of injecting and recent injection (adjusted odds ratio 0·7, 95% confidence interval 0·6-0·8, P = 0·05). Recruitment setting may have an impact on HCV prevalence estimates of IDUs in Europe. Assessing the impact of mixed recruitment strategies, including respondent-driven sampling, on HCV prevalence estimates, would be valuable. Epidemiol Infect. 2013 Mar;141(3):563-72. https://pmc.ncbi.nlm.nih.gov/articles/PMC9151900/ http://hdl.handle.net/20.500.12105/11500 22595549 10.1017/S0950268812000921 1469-4409 Epidemiology and infection Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: impact of study recruitment setting